Unite with Fellow Investors
Choose the Best Attorney
Follow Case Progress
id: 334, Created by Stan Vick Chase, Scout
Recro Pharma, Inc.
17 July 2017Class period Start
23 May 2018Class period End
08 October 2022Claim deadline
Recro Pharma agreed to pay $1.4 million to settle a securities class action lawsuit accusing the Company of deceiving investors about material information.
The original complaint alleged that the Company and its Leaders misled investors through a series of public statements regarding Recro’s target opportunities that allegedly inflated Recro’s stock price, in particular, they misrepresented and/or omitted Key Opinion Leader concerns about the drug IV meloxicam.
Recro Pharma agreed to settle with investors to avoid further litigation.
Pomerantz LLP, Kaskela Law LLC, Bronstein, Gewirtz & Grossman LLC
Eastern District of Pennsylvania
Hon. Michael M. Baylson
Strategic Claims Services
Court hearing date
26 October 2022
+$1,400,000Total Settlement Amount